ABBISKO-B (02256.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec22

NMPA Approves Equillium's Beijiemai® for Specific Patient Treatment

08:34

Dec16

Hengyue Biopharma's ABSK061 Completes First Patient Dosing in Phase II Clinical Trial for Achondroplasia Children

00:08

Dec8

Hualyx Pharmaceutical Announces Positive Phase II Clinical Study Results of ABSK043 Combined with Furmonetinib for NSCLC and Regulatory Approval for Further Studies

00:03

Dec1

Hengyuyao Subsidiary's ABSK141 Receives FDA Clinical Trial Approval

09:40

Nov17

Hubble Medicine Displays Global Phase III Study Results of Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

00:04

Nov4

UBS Recommends Buy Rating on Hua Medicine for Innovation in Oncology Drugs

03:38

Schedules & Filings

Schedules

Filings

Aug4

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 334.99 M, Net Income 179.76 M, EPS 0.2791

Mar3

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 3.574 M, Net Income -94.94 M, EPS -0.1509

HeYu Pharmaceutical 2024 Annual Performance Conference

Aug12

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 267.17 M, Net Income 111.1 M, EPS 0.1719

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change